title: Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.
abstract: Accumulation of β-amyloid (Aβ) and loss of synapses are hallmarks of Alzheimer's disease (AD). How synaptic activity relates to Aβ accumulation and loss of synapses is a current topic of major interest. Synaptic activation promotes Aβ secretion, and chronic reduction of synaptic activity reduced Aβ plaques in an AD transgenic mouse model. This suggested beneficial effects of reducing synaptic activity in AD. We now show that reduced synaptic activity causes detrimental effects on synapses and memory despite reducing plaques using two different models of chronic synaptic inhibition: deafferentation of the barrel cortex and administration of benzodiazepine. An interval of prolonged synaptic inhibition exacerbated loss of synaptophysin compared with synaptically more active brain in AD transgenic but not wild-type mice. Furthermore, an interval of benzodiazepine treatment, followed by a washout period, exacerbated memory impairment in AD transgenic mice. Exacerbation of synaptic and behavioral abnormalities occurred in the setting of reduced Aβ plaques but elevated intraneuronal Aβ immunoreactivity. These data support beneficial effects of synaptic activation on Aβ-related synaptic and behavioral impairment in AD.
authors.affiliation: Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York 10065, USA.
authors.forename: Davide
authors.initials: D
authors.lastname: Tampellini
authors.forename: Estibaliz
authors.initials: E
authors.lastname: Capetillo-Zarate
authors.forename: Magali
authors.initials: M
authors.lastname: Dumont
authors.forename: Zhenyong
authors.initials: Z
authors.lastname: Huang
authors.forename: Fangmin
authors.initials: F
authors.lastname: Yu
authors.forename: Michael T
authors.initials: MT
authors.lastname: Lin
authors.forename: Gunnar K
authors.initials: GK
authors.lastname: Gouras
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics* / Q000473:pathology / Q000523:psychology; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D015153:Blotting, Western; D002540:Cerebral Cortex / Q000473:pathology; D003975:Diazepam / Q000494:pharmacology; D005260:Female; D006624:Hippocampus / Q000473:pathology; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007150:Immunohistochemistry; D008297:Male; D018782:Maze Learning; D008568:Memory / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D009044:Motor Cortex / Q000473:pathology; D058225:Plaque, Amyloid / Q000473:pathology; D013569:Synapses / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D016708:Synaptophysin / Q000378:metabolism*; D014738:Vibrissae / Q000294:innervation / Q000502:physiology
chemical_list: D016229:Amyloid beta-Peptides; D006993:Hypnotics and Sedatives; D016708:Synaptophysin; D003975:Diazepam